Want to see HK:6826 full AI Analyst Report?
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) AI Stock Analysis
Shanghai Haohai Biological Technology Co., Ltd. Class H
(HKEX:6826)
The score is driven primarily by mixed financial performance: a low-debt balance sheet and positive cash generation support stability, but weakened growth and sharply compressed profitability meaningfully reduce quality. Technically, momentum remains soft with the stock below key longer-term moving averages and a negative MACD. Valuation is a headwind due to a very high P/E, partially offset by a strong dividend yield.
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 6.28B
- Dividend Yield
- 6.25%
- Average Volume (3M)
- 104.42K
- Price to Earnings (P/E)
- 58.7
- Beta (1Y)
- 0.65
- Revenue Growth
- -4.88%
- EPS Growth
- -68.62%
- Country
- Hong Kong
- Employees
- 2,110
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, an...
Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Financials are mixed: the balance sheet is strong with very low leverage, and cash flow remains positive in TTM, but operating performance has weakened materially with declining revenue and sharply compressed margins versus 2023–2024.
Income Statement
52NeutralBalance Sheet
78PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.27B | 2.45B | 2.68B | 2.63B | 2.10B | 1.75B |
| Gross Profit | 1.45B | 1.69B | 1.87B | 1.85B | 1.45B | 1.26B |
| EBITDA | 120.56M | 445.99M | 577.25M | 713.41M | 447.55M | 550.45M |
| Net Income | 101.96M | 244.51M | 420.45M | 416.12M | 180.47M | 352.23M |
Balance Sheet | ||||||
| Total Assets | 6.46B | 6.72B | 7.12B | 7.11B | 6.89B | 6.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.32B | 2.52B | 2.76B | 2.75B | 2.56B | 2.91B |
| Total Debt | 432.72M | 398.67M | 448.43M | 407.95M | 118.26M | 105.51M |
| Total Liabilities | 1.05B | 1.12B | 1.20B | 1.09B | 990.02M | 890.07M |
| Stockholders Equity | 5.26B | 5.42B | 5.58B | 5.65B | 5.51B | 5.71B |
Cash Flow | ||||||
| Free Cash Flow | 269.23M | 446.40M | 283.08M | 367.22M | -85.85M | 70.19M |
| Operating Cash Flow | 475.69M | 628.50M | 648.57M | 634.45M | 231.30M | 342.29M |
| Investing Cash Flow | 146.96M | -10.81M | 282.28M | -376.65M | -681.82M | -148.09M |
| Financing Cash Flow | -387.88M | -509.70M | -390.35M | -257.73M | -288.35M | -231.25M |
Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Negative. The current price of 15.63 is below the 20-day moving average (MA) of 15.84, below the 50-day MA of 16.07, and below the 200-day MA of 19.02, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 65.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6826.
Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison
Overall Rating
HK:226981Outperform
HK:154871Outperform
HK:269664.6Neutral- HK:682659Neutral
HK:375953Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2269 | 81Outperform | HKD 183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% |
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:6826 | 59Neutral | HKD 7.12B | 58.69 | 2.04% | 6.25% | -4.88% | -68.62% |
| HK:3759 | 53Neutral | HKD 80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6826 | Shanghai Haohai Biological Technology Co., Ltd. Class H | 15.63 | -10.65 | -40.53% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:3759 | Pharmaron Beijing Co., Ltd. Class H | 26.98 | 1.65 | 6.50% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Haohai Warns on Investment Risks as Q3 2026 Profits Slump
Shanghai Haohai Biological Technology Co., Ltd., a Hong Kong and Shanghai-listed biopharmaceutical company, has released unaudited financial figures for the third quarter and first nine months of 2026 prepared under Chinese Accounting Standards. The...
Shanghai Haohai Bio-Tech Sets Board Meeting to Approve Q3 2026 Results
Shanghai Haohai Biological Technology has scheduled a board meeting for 23 October 2026 to review and approve its third-quarter results for the nine months ended 30 September 2026. The company plans to publish these quarterly figures after board appr...
Shanghai Haohai Biological Profit Slumps on Lower Revenue, Dividend Cut
Shanghai Haohai Biological Technology reported interim unaudited revenue of RMB1.17 billion for the six months ended 30 June 2026, down 9.81% from a year earlier. Net profit attributable to shareholders fell 46.64% to RMB112.63 million, while earning...
Shanghai Haohai Biological Declares 2026 Interim Dividend and Sets Payout Timetable
Shanghai Haohai Biological Technology has approved an interim dividend of RMB0.25 per share for the six months ended 30 June 2026, reflecting the board’s assessment of interim results and capital needs. After excluding treasury shares and repur...
Shanghai Haohai Biotech Reshuffles Hong Kong Authorized Representatives
Shanghai Haohai Biological Technology Co., Ltd. has announced changes to its authorized representatives under Hong Kong listing rules. Non‑executive director Huang Ming will step down from the role, while executive director and joint company se...
Shanghai Haohai Biological Declares Interim Dividend and Details Withholding Tax Rules
Shanghai Haohai Biological Technology has declared an interim ordinary cash dividend of RMB 0.25 per share for the six months ended 30 June 2026, payable in Hong Kong dollars at HKD 0.288995 per share. The dividend, relating to the financial year end...
Shanghai Haohai Sets August Board Meeting to Review Interim Results and Dividend
Shanghai Haohai Biological Technology Co., Ltd. has scheduled a board meeting for 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the publication of these results and the po...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026